Report Description Table of Contents What Is the Targeted Sequencing & Resequencing Market Size and What Is Shaping Its Commercial and Clinical Landscape?– (Updated On: 28-Aug-2026) The Global Targeted Sequencing & Resequencing Market was valued at USD 9.40 billion in 2025 and is projected to reach USD 35.43 billion by 2032, expanding at a CAGR of 20.9% during 2026-2032, according to Strategic Market Research. The targeted sequencing and resequencing market covers technologies used to study selected genes or genomic regions for faster and more focused genetic analysis. Demand is growing across cancer diagnostics, inherited disease testing, rare disease screening, and precision medicine, where laboratories need accurate results without sequencing the entire genome. The approach can lower testing complexity, shorten analysis time, and support more routine use of genomic testing in clinical laboratories. Companies such as Illumina offer targeted sequencing panels for oncology and genetic disease applications, while Thermo Fisher Scientific provides targeted sequencing solutions used by hospitals, diagnostic laboratories, and research institutions. Targeted sequencing and resequencing is gaining commercial momentum as laboratories seek higher throughput, lower per-sample costs, and more efficient genomic testing workflows. CRISPR-based enrichment is expanding the range of targeted applications, while high-throughput sequencing platforms are helping laboratories process larger testing volumes without a similar increase in operating costs. MGI’s DNBSEQ-T7 Plus is positioned for high-volume sequencing environments and large genomic programs. What Are the Key Targeted Sequencing & Resequencing Market Takeaways? By Type DNA-Based Targeted Sequencing: Held 70% of the market at USD 6.58 billion in 2025 and is projected to grow at a CAGR of 20.0%, leading tumor, germline and research variant analysis. RNA-Based Targeted Sequencing: Accounted for 30% and USD 2.82 billion in 2025 and is projected to grow at a CAGR of 22.8%, adding fusion, splice-variant and transcript analysis. By Technology Sequencing: Held 69% of the market at USD 6.49 billion in 2025 and is projected to grow at a CAGR of 20.0%, covering first-pass targeted analysis. Resequencing: Accounted for 31% and USD 2.91 billion in 2025 and is projected to grow at a CAGR of 22.7%, supporting reference-based variant discovery, confirmation and comparison. By Application Clinical Applications: Led with 52% and USD 4.89 billion in 2025 and are projected to grow at a CAGR of 21.2%, supported by oncology, inherited-disease testing and minimal residual disease analysis. Plant & Animal Sciences: Represented 15% and USD 1.41 billion in 2025 and are projected to grow at a CAGR of 18.5%, covering breeding, trait analysis and veterinary genomics. Drug Development: Held 23% and USD 2.16 billion in 2025 and is projected to grow at the fastest application CAGR of 23.0% as biomarker and companion-diagnostic programs scale. Others: Accounted for 10% and USD 0.94 billion in 2025 and are projected to grow at a CAGR of 17.0%, including forensic, food-testing and environmental applications. By End User Hospitals & Clinics: Led with 46% and USD 4.32 billion in 2025 and are projected to grow at a CAGR of 22.0%, as clinical laboratories integrate sequencing into patient-testing and treatment-selection pathways. Academic Research: Represented 38% and USD 3.57 billion in 2025 and is projected to grow at a CAGR of 19.5%, prioritizing configurable panels, biomarker research and validation studies. Others: Accounted for 16% and USD 1.50 billion in 2025 and are projected to grow at a CAGR of 20.7%, including biopharmaceutical companies, CROs and specialist laboratories. By Geography North America: Led with 45% and USD 4.23 billion in 2025 and is projected to grow at a CAGR of 19.5%, benefiting from established molecular laboratories and genomic-testing payer pathways. Europe: Represented 25% and USD 2.35 billion in 2025 and is projected to grow at a CAGR of 20.0%, as public laboratories and national genomic programs shape testing and purchasing. Asia-Pacific: Held 22% and USD 2.07 billion in 2025 and is projected to record the fastest regional CAGR of 24.0% as genomic infrastructure and testing capacity expand. Latin America: Accounted for 5% and USD 0.47 billion in 2025 and is projected to grow at a CAGR of 22.0%, with centralized sequencing and reference-laboratory services remaining important. Middle East & Africa: Represented 3% and USD 0.28 billion in 2025 and are projected to grow at a CAGR of 21.1%, with activity concentrated in national genomics programs and tertiary-care hubs. Where Is Revenue Generated Across the Targeted Sequencing & Resequencing Workflow? Revenue spans panel design, enrichment, library preparation, sequencing, bioinformatics, interpretation, maintenance and services. Instruments establish workflows; recurring probes, primers, library kits, flow cells, software and support drive lifetime value. Central laboratories add per-test revenue, while biopharma buys assay development, biomarker testing and data services. By Type DNA-based targeted sequencing accounted for 70% or USD 6.58 billion in 2025 and is projected at 20.0%. It leads because substitutions, indels, copy-number changes and inherited variants are central to tumor and germline testing. Guardant360 Liquid CDx and Tempus xT CDx illustrate blood- and tissue-based models. [2] [8] RNA-based targeted sequencing represented 30% or USD 2.82 billion and is projected at 22.8%. RNA panels add fusion, splice-variant and expression information that DNA-only assays may miss. Oncomine Dx Express combines DNA alterations with RNA fusions and splice variants. [3] [4] By Technology Sequencing held 69% or USD 6.49 billion in 2025 and is projected at 20.0%. Strategic Market Research defines it as first-pass targeted analysis in clinical, research or development workflows. NextSeq 550Dx and Genexus Dx demonstrate integrated instrument, assay and bioinformatics models. [3] [4] Resequencing accounted for 31% or USD 2.91 billion and is forecast at 22.7%. It means analysis of predefined regions against a reference for discovery, confirmation or comparison—not simply repeat patient testing. Industry terminology overlaps; configurable capture systems support this work. [1] [20] [21] [23] [24] Which Applications and End Users Are Expanding the Targeted Sequencing & Resequencing Market? Clinical applications accounted for 52% or USD 4.89 billion in 2025 and are projected at 21.2%. Oncology provides the clearest reimbursed pathway through profiling, companion diagnostics, liquid biopsy and MRD. In a 2019-2022 C-CAT cohort of 30,822 cases, treatment options were presented in 44.5% and administered in 9.4%. [2] [3] [4] [5] Plant and animal sciences represented 15% or USD 1.41 billion and are forecast at 18.5%. Shared enrichment and sequencing infrastructure supports breeding, traits, veterinary genetics and disease-resistance research. Project-based purchasing moderates growth versus clinical and drug-development uses. Drug development held 23% or USD 2.16 billion and is projected at 23.0%. Biopharma uses targeted sequencing for biomarkers, stratification, pharmacogenomics and companion diagnostics. GuardantINFINITY and Tempus extend revenue into regulatory support, data licensing and trial services. [6] [7] Other applications accounted for 10% or USD 0.94 billion and are forecast at 17.0%. Forensic, food and environmental testing remain fragmented; custom design, multiplexing and sample compatibility matter more than reimbursement. Hospitals and clinics, including clinical laboratories, held 46% or USD 4.32 billion and are projected at 22.0%. Buyers assess validation, turnaround time, automation, bioinformatics and reimbursement together. The Royal Marsden's five-year clonoSEQ award spans kits, reagents, software, training and support.[15] Academic and research institutes represented 38% or USD 3.57 billion and are forecast at 19.5%. They prioritize customization, uniformity, sample flexibility and sequencer compatibility. SureSelect, QIAseq, KAPA, Twist and xGen cover hybrid-capture and amplicon workflows.[20] [21] [22] [23] [24] Other end users held 16% or USD 1.50 billion and are projected at 20.7%. Biopharma and CROs buy project-based biomarker and data services; reference laboratories build recurring volumes around ordering, reimbursement and throughput. Public-health laboratories add surveillance uses. How Are Coverage, Payment and Testing Utilization Shaping the Targeted Sequencing & Resequencing Market? CMS NCD 90.2 covers qualifying somatic and germline cancer NGS tests when patient, laboratory, physician-order and FDA companion-diagnostic criteria are met; MACs may cover other eligible tests. CMS applies no CLFS phase-in reduction in 2026, while annual reductions from 2027 through 2029 may not exceed 15%. [9] [10] Coverage does not ensure uniform payment or use. A 2025 JAMA analysis found 23.3% of 29,919 cancer-related Medicare NGS claims from 2016-2021 were denied. A 2026 study of 391,151 beneficiaries found overall genomic testing rose from 6.0% in 2016 to 16.7% in 2023, although NGS use remained modest. [11] [12] National systems create different purchasing routes. NHS England publishes Q4 2025/26 activity by national and Genomic Laboratory Hub level and reported more than 809,000 genomic reports in 2023/24; that broader figure is not targeted-panel volume. Japan reimburses D006-19 cancer genomic profiling at 44,000 points, while C-CAT links testing with clinical data. [13] [14] [5] Which Regions Offer the Strongest Commercial Opportunity in the Targeted Sequencing & Resequencing Market? North America accounted for an estimated 45% or USD 4.23 billion in 2025 and is projected at 19.5%. FDA-approved assays, Medicare pathways, reference laboratories and in-house platforms support centralized and hospital workflows. Guardant, Tempus, Illumina and Thermo Fisher span service, data and platform models. [2] [3] [4] [7] [9] Europe represented 25% or USD 2.35 billion and is forecast at 20.0%. UK laboratory hubs and procurement provide visible purchasing evidence, while the EU's 1+ Million Genomes initiative builds cross-border data infrastructure. Guardant at Policlinico Gemelli and Adaptive's Royal Marsden award illustrate service and specialist-assay models. [6] [13] [15] [16] Asia-Pacific held 22% or USD 2.07 billion and is projected at 24.0%. Japan provides the clearest documented clinical pathway through C-CAT and D006-19 reimbursement. Australia established Genomics Australia in July 2025 to coordinate national implementation. [5] [14] [17] Latin America represented 5% or USD 0.47 billion and is forecast at 22.0%. Brazil's Genomas Brasil is building precision-health and genomic-data capabilities, while commercial testing remains concentrated in specialist and reference laboratories. Centralized services reduce local infrastructure requirements. [18] Middle East & Africa held 3% or USD 0.28 billion and is projected at 21.1%. The UAE reported over 700,000 Emirati Genome Program samples by March 2025, while Saudi strategy includes genomic databases and analytics. These are infrastructure indicators, not targeted-panel volumes. [19] How Are Platform, Panel and Testing-Service Companies Competing in the Targeted Sequencing & Resequencing Market? Competition centers on enrichment, panel content, sample input, turnaround time, automation, bioinformatics and workflow support. FDA-approved diagnostics compete on clinical utility; research-use-only suppliers on design flexibility; service providers on ordering reach, data integration and per-test economics. Illumina TruSight Oncology Comprehensive and NextSeq 550Dx combine a regulated assay with an established platform. The August 2026 RET companion-diagnostic supplement added clinical value; Illumina also supplies research panels and enrichment. [4] [1] Thermo Fisher Scientific Ion Torrent, Genexus and Oncomine support automated in-house testing. FDA-approved Oncomine Dx Express detects alterations in 42 DNA genes, copy changes in 10 genes, and fusions or splice variants in 18 RNA genes. [3] Guardant Health Guardant360 Liquid CDx uses plasma cfDNA and hybrid capture across 741 genes; negative labeled biomarkers should be reflexed to tissue when feasible. Guardant also spans tissue profiling, recurrence monitoring and biopharma services. [2] [6] Tempus AI The 648-gene xT CDx anchors tissue profiling; a 2026 FDA supplement added an alternative germline-subtraction method. xF was submitted to FDA and xR remained a company-disclosed PMA program. The proposed Personalis acquisition would deepen tumor-informed MRD if completed. [7] [8] Roche Diagnostics KAPA HyperCap uses hybrid capture and KAPA HyperPETE primer extension. HyperDesign supports custom human and non-human panels; many products are research-use-only. [20] Adaptive Biotechnologies clonoSEQ occupies a specialized hematologic-MRD position built on repeat testing, software and support, illustrated by The Royal Marsden's five-year award. [15] Agilent Technologies SureSelect and SureDesign support custom hybrid-capture panels across coding, non-coding and transcriptomic regions, competing on design and automation compatibility. [21] QIAGEN QIAseq targeted DNA panels combine molecular barcodes with multiplex PCR to support low-frequency variant detection and integrated analysis. [22] Twist Bioscience Twist offers predesigned and custom DNA, RNA, methylation, exome and non-human panels, emphasizing uniform capture and scalable manufacturing. [23] Integrated DNA Technologies IDT's xGen custom and predesigned capture panels use individually synthesized probes for flexible research design and sequencer integration. [24] What Is the Research Scope and Methodology for the Targeted Sequencing & Resequencing Market? Market estimates: The 2025 market size, forecast value, 20.9% headline CAGR, segment shares and segment growth rates in this RD are Strategic Market Research estimates. Segment dollar values are calculated from the approved 2025 global baseline. Shares and values are rounded and should be maintained consistently across the full report, landing page, charts and FAQs. The technology split between targeted sequencing and targeted resequencing is based on Strategic Market Research’s allocation methodology because the two terms and workflows overlap in commercial and industry usage.[1] Technology, clinical and commercial verification: Market evidence was reviewed using FDA, CMS, NHS England, Japan’s MHLW and C-CAT, peer-reviewed studies, SEC filings, government genomic programs, procurement notices and official supplier materials. Technology definitions and targeted resequencing workflows were cross-checked against sequencing platform documentation, while clinical adoption, reimbursement, genomic testing programs, regulatory status, product launches and company developments were verified using primary or authoritative sources wherever available. These external sources support utilization trends, technology adoption, product status and commercial context but do not independently validate Strategic Market Research’s proprietary market estimates. Targeted Sequencing & Resequencing Market Report Coverage Table Report Coverage Details Forecast Period 2026–2032 Market Size Value in 2025 USD 9.40 Billion Revenue Forecast in 2032 USD 35.43 Billion Overall Growth Rate CAGR of 20.9% (2026–2032) Base Year 2025 Historical Data 2019–2024 Unit USD Billion, CAGR (2026–2032) Segmentation By Type, By Technology, By Application, By End User, By Geography By Type DNA-Based Targeted Sequencing, RNA-Based Targeted Sequencing By Technology Sequencing, Resequencing By Application Clinical Applications, Plant & Animal Sciences, Drug Development, Others By End User Hospitals & Clinics, Academic Research, Others By Geography North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Brazil, Argentina, Saudi Arabia, United Arab Emirates, South Africa Market Drivers Expanding cancer and inherited-disease testing, growing precision-medicine adoption, higher sequencing throughput, lower per-sample costs, CRISPR-based enrichment, recurring consumables and software revenue, broader reimbursement pathways, and national genomic programs Customization Option Available upon request Frequently Asked Question About This Report Q1. What are the key trends shaping the industry? A1. Growth is being shaped by wider clinical genomic testing, increasing use of liquid biopsy and MRD assays, and stronger integration of sequencing with precision medicine. Laboratories are also moving toward higher-throughput workflows, automated sample preparation, and recurring software-driven interpretation. Q2. Which industries are using this technology the most in the market? A2. Healthcare and biopharmaceutical companies are the largest commercial users. Hospitals use targeted panels for cancer and inherited-disease testing, while drug developers apply them to biomarker discovery, patient stratification, companion diagnostics, and clinical trials. Academic research and agricultural genomics provide additional demand. Q3. What factors are supporting growth across major regions in the market? A3. North America benefits from established molecular laboratories, FDA-approved assays, and Medicare coverage pathways. Europe is expanding national genomic infrastructure, while Asia-Pacific is growing faster through new sequencing capacity, national genomics initiatives, and increasing clinical adoption in countries such as Japan and Australia. Q4. What are the most promising applications expected to grow in the industry? A4. Drug development is one of the fastest-growing opportunities as pharmaceutical companies expand biomarker-guided trials and companion diagnostics. Clinical oncology also remains highly attractive through tumor profiling, liquid biopsy, inherited-cancer testing, and minimal residual disease monitoring. Q5. How are companies improving their products and solutions in the market? A5. Companies are improving automation, panel customization, RNA and DNA analysis, low-input sample performance, and bioinformatics integration. Illumina, Thermo Fisher, Guardant, Tempus, Roche, Agilent, QIAGEN, Twist, and IDT are also expanding panel breadth and workflow flexibility for clinical and research users. Q6. Why are companies investing in this technology in the industry? A6. Targeted approaches can provide clinically useful genomic information without the cost and analytical burden of sequencing an entire genome. They also create recurring revenue through enrichment kits, library reagents, flow cells, software, interpretation, and testing services after platforms are installed. Q7. What factors could limit future market growth? A7. Reimbursement variability, denied claims, laboratory-validation requirements, bioinformatics complexity, and differences in national testing pathways can slow adoption. Growth also depends on demonstrating clinical utility because broader sequencing availability does not automatically translate into routine testing or treatment changes. Sources: 1. Targeted sequencing definitions; PMC study 2. Guardant360 Liquid CDx (P250027) 3. Oncomine Dx Express (P240040) 4. TruSight Oncology Comprehensive (S006) 5. C-CAT registration statistics 6. Guardant Health 2025 Form 10-K 7. Tempus AI Q2 2026 results 8. Tempus xT CDx; 2026 supplement 9. CMS NCD 90.2 10. CMS 2026 CLFS/PAMA 11. Medicare NGS claim denials 12. Medicare genomic-testing uptake 13. NHS genomic activity; Performance 14. Japan D006-19 reimbursement 15. clonoSEQ; Royal Marsden 16. EU 1+ Million Genomes 17. Australia genomics framework 18. Genomas Brasil 19. Gulf genome strategies; Saudi Arabia 20. Roche KAPA enrichment 21. Agilent SureSelect 22. QIAGEN QIAseq 23. Twist target enrichment 24. IDT xGen capture panels Table of Contents - Global Targeted Sequencing & Resequencing Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Type, Technology, Application, End User, and Geography Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Type, Technology, Application, End User, and Geography Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Type, Technology, Application, and End User Investment Opportunities in the Targeted Sequencing & Resequencing Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Oncology Testing, Inherited-Disease Testing, Rare Disease Screening, Precision Medicine, Biomarker Programs, Companion Diagnostics, and Genomic Research Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Targeted Sequencing and Resequencing in Clinical Genomics, Drug Development, and Research Applications Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory, Reimbursement, and Clinical Validation Factors Role of High-Throughput Sequencing, Target Enrichment, Automation, Bioinformatics, and Molecular Testing in Market Expansion Coverage, Payment, Testing Utilization, Sample Quality, and Workflow Efficiency Trends in Targeted Genomic Testing Global Targeted Sequencing & Resequencing Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Type: DNA-Based Targeted Sequencing RNA-Based Targeted Sequencing Market Analysis by Technology: Sequencing Resequencing Market Analysis by Application: Clinical Applications Plant & Animal Sciences Drug Development Others Market Analysis by End User: Hospitals & Clinics Academic Research Others Market Analysis by Geography: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Targeted Sequencing & Resequencing Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Type, Technology, Application, and End User Country-Level Breakdown: United States Canada Mexico Europe Targeted Sequencing & Resequencing Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Type, Technology, Application, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Russia Rest of Europe Asia Pacific Targeted Sequencing & Resequencing Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Type, Technology, Application, and End User Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Targeted Sequencing & Resequencing Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Type, Technology, Application, and End User Country-Level Breakdown: Brazil Argentina Rest of Latin America Middle East & Africa Targeted Sequencing & Resequencing Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Type, Technology, Application, and End User Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Illumina, Inc. Thermo Fisher Scientific Inc. Guardant Health, Inc. Tempus AI, Inc. Roche Diagnostics Adaptive Biotechnologies Corporation Agilent Technologies, Inc. QIAGEN N.V. Twist Bioscience Corporation Integrated DNA Technologies BGI Genomics Co., Ltd. Personalis, Inc. Oxford Nanopore Technologies plc PacBio Competitive Landscape and Strategic Insights Benchmarking Based on Target Enrichment, Panel Breadth, Sequencing Platform Compatibility, Automation, Bioinformatics, Clinical Validation, Regulatory Positioning, and Regional Presence Clinical Testing, Companion Diagnostics, Research-Use-Only Positioning, and Service Capability Analysis Targeted Panel Development and Assay Portfolio Positioning Oncology, Inherited-Disease, Rare-Disease, and Minimal Residual Disease Competitiveness Biomarker, Pharmacogenomics, Companion-Diagnostic, and Drug-Development Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Type, Technology, Application, End User, and Geography (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Vendors Clinical, Regulatory, Reimbursement, and Procurement Analysis Technology Adoption Trends Across Target Enrichment, Sequencing, Resequencing, Bioinformatics, Automation, and Testing Services List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Type, Technology, Application, and End User (2025 vs. 2032) Global Targeted Sequencing & Resequencing Ecosystem and Value Chain Analysis